Limits...
Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates.

Jung KY, Cho SW, Kim YA, Kim D, Oh BC, Park do J, Park YJ - J Pathol Transl Med (2015)

Bottom Line: The histological subtypes in thyroid cancer exhibited significantly different CD163-positive macrophages densities (papillary, 1.8 ± 1.6% vs anaplastic, 22.9 ± 17.1%; p < .001), but no significant difference between histological subtypes was detected in lung and breast cancers.Moreover, there was no significant difference in CD163-positive macrophages densities among the TNM stages in lung, breast, and thyroid cancers.Cancers with higher TAM densities (pancreas, lung, anaplastic thyroid, and gallbladder) were associated with poor survival rate.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea ; Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Macrophages are a component of a tumor's microenvironment and have various roles in tumor progression and metastasis. This study evaluated the relationships between tumor-associated macrophage (TAM) density and clinical outcomes in 14 different types of human cancers.

Methods: We investigated TAM density in human tissue microarray sections from 14 different types of human cancers (n = 266) and normal thyroid, lung, and breast tissues (n = 22). The five-year survival rates of each cancer were obtained from the 2011 Korea Central Cancer Registry.

Results: Among 13 human cancers, excluding thyroid cancer, pancreas, lung, and gallbladder cancers had the highest density of CD163-positive macrophages (7.0±3.5%, 6.9±7.4%, and 6.9 ± 5.5%, respectively). The five-year relative survival rates of these cancers (pancreas, 8.7%; lung, 20.7%; gallbladder, 27.5%) were lower than those of other cancers. The histological subtypes in thyroid cancer exhibited significantly different CD163-positive macrophages densities (papillary, 1.8 ± 1.6% vs anaplastic, 22.9 ± 17.1%; p < .001), but no significant difference between histological subtypes was detected in lung and breast cancers. Moreover, there was no significant difference in CD163-positive macrophages densities among the TNM stages in lung, breast, and thyroid cancers.

Conclusions: Cancers with higher TAM densities (pancreas, lung, anaplastic thyroid, and gallbladder) were associated with poor survival rate.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical staining for CD163 in breast cancer. Representative CD163 staining in breast cancer. TAM density was measured by averaging the CD163-positive area (%) of five different sites in each tissue (A). The positive IHC staining area (%) was separated and calculated using the Image J color deconvolution plugin (B, C).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508569&req=5

f1-jptm-49-4-318: Immunohistochemical staining for CD163 in breast cancer. Representative CD163 staining in breast cancer. TAM density was measured by averaging the CD163-positive area (%) of five different sites in each tissue (A). The positive IHC staining area (%) was separated and calculated using the Image J color deconvolution plugin (B, C).

Mentions: CD68 and CD163 were used as TAM markers. Immunohistochemical (IHC) staining for CD68 and CD163 was performed using the BenchMark XT Slide Preparation System (Ventana Medical Systems, Tucson, AZ, USA) and CD68 (ready-to-use, 514H12, Novocastra, Newcastle upon Tyne, UK) and CD163 (1:200, 10D6, ER2, Novocastra). The proportion of CD163-positive area in each tumor was evaluated after IHC staining (Fig. 1). We divided the area of each tissue core into quarters and a central area and randomly chose all five fragments to determine the positive stain proportion (Fig. 1A). Areas of fibrosis or tumor necrosis among the randomly chosen fragments were excluded. We used a color deconvolution plug-in for Image J software to identify the positive stains and to calculate the percent CD163-positive area (Fig. 1B, C). TAM density was determined by calculating the average CD163-positive area (%) at a minimum of four different sites in each tissue.


Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates.

Jung KY, Cho SW, Kim YA, Kim D, Oh BC, Park do J, Park YJ - J Pathol Transl Med (2015)

Immunohistochemical staining for CD163 in breast cancer. Representative CD163 staining in breast cancer. TAM density was measured by averaging the CD163-positive area (%) of five different sites in each tissue (A). The positive IHC staining area (%) was separated and calculated using the Image J color deconvolution plugin (B, C).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508569&req=5

f1-jptm-49-4-318: Immunohistochemical staining for CD163 in breast cancer. Representative CD163 staining in breast cancer. TAM density was measured by averaging the CD163-positive area (%) of five different sites in each tissue (A). The positive IHC staining area (%) was separated and calculated using the Image J color deconvolution plugin (B, C).
Mentions: CD68 and CD163 were used as TAM markers. Immunohistochemical (IHC) staining for CD68 and CD163 was performed using the BenchMark XT Slide Preparation System (Ventana Medical Systems, Tucson, AZ, USA) and CD68 (ready-to-use, 514H12, Novocastra, Newcastle upon Tyne, UK) and CD163 (1:200, 10D6, ER2, Novocastra). The proportion of CD163-positive area in each tumor was evaluated after IHC staining (Fig. 1). We divided the area of each tissue core into quarters and a central area and randomly chose all five fragments to determine the positive stain proportion (Fig. 1A). Areas of fibrosis or tumor necrosis among the randomly chosen fragments were excluded. We used a color deconvolution plug-in for Image J software to identify the positive stains and to calculate the percent CD163-positive area (Fig. 1B, C). TAM density was determined by calculating the average CD163-positive area (%) at a minimum of four different sites in each tissue.

Bottom Line: The histological subtypes in thyroid cancer exhibited significantly different CD163-positive macrophages densities (papillary, 1.8 ± 1.6% vs anaplastic, 22.9 ± 17.1%; p < .001), but no significant difference between histological subtypes was detected in lung and breast cancers.Moreover, there was no significant difference in CD163-positive macrophages densities among the TNM stages in lung, breast, and thyroid cancers.Cancers with higher TAM densities (pancreas, lung, anaplastic thyroid, and gallbladder) were associated with poor survival rate.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea ; Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.

ABSTRACT

Background: Macrophages are a component of a tumor's microenvironment and have various roles in tumor progression and metastasis. This study evaluated the relationships between tumor-associated macrophage (TAM) density and clinical outcomes in 14 different types of human cancers.

Methods: We investigated TAM density in human tissue microarray sections from 14 different types of human cancers (n = 266) and normal thyroid, lung, and breast tissues (n = 22). The five-year survival rates of each cancer were obtained from the 2011 Korea Central Cancer Registry.

Results: Among 13 human cancers, excluding thyroid cancer, pancreas, lung, and gallbladder cancers had the highest density of CD163-positive macrophages (7.0±3.5%, 6.9±7.4%, and 6.9 ± 5.5%, respectively). The five-year relative survival rates of these cancers (pancreas, 8.7%; lung, 20.7%; gallbladder, 27.5%) were lower than those of other cancers. The histological subtypes in thyroid cancer exhibited significantly different CD163-positive macrophages densities (papillary, 1.8 ± 1.6% vs anaplastic, 22.9 ± 17.1%; p < .001), but no significant difference between histological subtypes was detected in lung and breast cancers. Moreover, there was no significant difference in CD163-positive macrophages densities among the TNM stages in lung, breast, and thyroid cancers.

Conclusions: Cancers with higher TAM densities (pancreas, lung, anaplastic thyroid, and gallbladder) were associated with poor survival rate.

No MeSH data available.


Related in: MedlinePlus